{"id":1440,"date":"2021-04-22T14:49:48","date_gmt":"2021-04-22T13:49:48","guid":{"rendered":"https:\/\/www.simcardiotest.eu\/wordpress\/?page_id=1440"},"modified":"2023-01-11T15:57:32","modified_gmt":"2023-01-11T14:57:32","slug":"drug-efficacy-cardiotoxicity","status":"publish","type":"page","link":"https:\/\/www.simcardiotest.eu\/wordpress\/methodology\/drug-efficacy-cardiotoxicity\/","title":{"rendered":"Drugs, efficacy & cardiotoxicity"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Procedure description<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Project leader<\/span>\nUniversitat Polit\u00e8cnica de Val\u00e8ncia (UPV)<\/a><\/p>\n

The objective here, is to to set up use cases on the use of in-silico models for the simulation of drug efficacy, safety and cardiotoxicity.<\/p>\n

Models for drug-ion channel interaction will be developed taking into consideration the plasmatic concentrations derived from pharmacokinetic and pharmacodynamic studies.<\/p>\n

The models will be used to analyse the effects of drugs at a multi-scale level from cell to organ, in normal and pathological conditions, such as ischemia, heart failure or atrial fibrillation. Personalised models will be built according to the standardisation process, as well as populations of models where variability will be taken into account. Differences in gender and age will also be considered. Specific biomarkers to assess drug efficacy and safety will be defined.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t
The receiver operating characteristic curve biomarkers @UPV<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Course of action<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
  1. Development of drug ion channel interaction models and assess drug effects at the cellular level in healthy and pathological virtual populations.<\/li>
  2. Integration of predictive personalised pharmacokinetics into in-silico medicine research via individualised computer modelling.<\/li>
  3. Assessment of the effects of drugs in validated, anatomically-based multi-scale predictive cardiac models for healthy and patient-specific disease conditions.<\/li>
  4. Identification of selective and specific biomarkers to improve prediction of drug efficacy and safety.<\/li><\/ol>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t\t\t